Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human

SIMPLE SUMMARY: The overall survival of ovarian cancer (OC) remains poor for most patients. Despite incorporation of novel therapeutic agents such as bevacizumab and PARP inhibitors to OC standard-of-care, efficacy is only observed in a subset of patients. Cancer vaccination has demonstrated effecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Cheryl Lai-Lai, Rovelli, Raphaël, Sarivalasis, Apostolos, Kandalaft, Lana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469371/
https://www.ncbi.nlm.nih.gov/pubmed/34572778
http://dx.doi.org/10.3390/cancers13184553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469371/
https://www.ncbi.nlm.nih.gov/pubmed/34572778
http://dx.doi.org/10.3390/cancers13184553

Ejemplares similares